Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM.

Clin Cancer Res. 2009 Mar 1;15(5):1585-92. doi: 10.1158/1078-0432.CCR-08-2068.

2.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
3.

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F.

Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review.

PMID:
18393776
4.

Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Boeckx C, Baay M, Wouters A, Specenier P, Vermorken JB, Peeters M, Lardon F.

Oncologist. 2013;18(7):850-64. doi: 10.1634/theoncologist.2013-0013. Review.

5.

Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.

Sharafinski ME, Ferris RL, Ferrone S, Grandis JR.

Head Neck. 2010 Oct;32(10):1412-21. doi: 10.1002/hed.21365. Review.

6.

Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Wheeler DL, Dunn EF, Harari PM.

Nat Rev Clin Oncol. 2010 Sep;7(9):493-507. doi: 10.1038/nrclinonc.2010.97. Review.

7.

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Brand TM, Iida M, Wheeler DL.

Cancer Biol Ther. 2011 May 1;11(9):777-92. Review.

8.

Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Markovic A, Chung CH.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1149-59. doi: 10.1586/era.12.91. Review.

9.

Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.

Harari PM, Wheeler DL, Grandis JR.

Semin Radiat Oncol. 2009 Jan;19(1):63-8. doi: 10.1016/j.semradonc.2008.09.009. Review.

10.

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA.

Drug Resist Updat. 2011 Dec;14(6):260-79. doi: 10.1016/j.drup.2011.08.002. Review.

11.

Targeting EGFR resistance networks in head and neck cancer.

Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS.

Cell Signal. 2009 Aug;21(8):1255-68. doi: 10.1016/j.cellsig.2009.02.021. Review.

12.

Nuclear EGFR as a molecular target in cancer.

Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL.

Radiother Oncol. 2013 Sep;108(3):370-7. doi: 10.1016/j.radonc.2013.06.010. Review.

13.

Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.

Cassell A, Grandis JR.

Expert Opin Investig Drugs. 2010 Jun;19(6):709-22. doi: 10.1517/13543781003769844. Review.

14.

The quest to overcome resistance to EGFR-targeted therapies in cancer.

Chong CR, Jänne PA.

Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Review.

15.

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.

Wykosky J, Fenton T, Furnari F, Cavenee WK.

Chin J Cancer. 2011 Jan;30(1):5-12. Review.

16.
17.

Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.

Morse L.

ONS News. 2006;21(8 Suppl):59-60. Review. No abstract available.

PMID:
16925155
18.

Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit.

Johnson DE.

Chin J Cancer. 2012 Jul;31(7):319-26. doi: 10.5732/cjc.011.10404. Review.

19.

Emerging drugs to treat squamous cell carcinomas of the head and neck.

Fung C, Grandis JR.

Expert Opin Emerg Drugs. 2010 Sep;15(3):355-73. doi: 10.1517/14728214.2010.497754. Review.

20.
Items per page

Supplemental Content

Support Center